Compare VVV & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVV | LQDA |
|---|---|---|
| Founded | 1866 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.1B |
| IPO Year | 2016 | 2018 |
| Metric | VVV | LQDA |
|---|---|---|
| Price | $30.31 | $35.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | ★ $38.73 | $37.40 |
| AVG Volume (30 Days) | ★ 2.9M | 1.1M |
| Earning Date | 02-05-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.93 | N/A |
| EPS | ★ 1.64 | N/A |
| Revenue | ★ $1,710,300,000.00 | $69,216,000.00 |
| Revenue This Year | $21.09 | $994.17 |
| Revenue Next Year | $9.85 | $169.25 |
| P/E Ratio | $18.16 | ★ N/A |
| Revenue Growth | 5.64 | ★ 343.41 |
| 52 Week Low | $29.29 | $11.26 |
| 52 Week High | $41.33 | $36.41 |
| Indicator | VVV | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 64.59 |
| Support Level | $29.36 | $33.45 |
| Resistance Level | $31.24 | $36.11 |
| Average True Range (ATR) | 0.94 | 1.46 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 37.19 | 85.58 |
Valvoline Inc provides automotive preventive maintenance through retail stores across the U.S. and Canada, offering approximately 15-minute stay-in-your-car oil changes, battery, bulb, and wiper replacements, tire rotations, and other manufacturer-recommended maintenance. Its full-service oil changes include Valvoline oil, a new oil filter, chassis lubrication, and an 18-point maintenance check. The Company provides differential fluid, fuel system cleaning, headlight and taillight replacement, radiator service, transmission service, air conditioning, and air filter replacement. It operates and franchises approximately 2,200 Valvoline Instant Oil Change and Valvoline Great Canadian Oil Change retail locations. The majority of revenue is generated from the United States of America.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.